Samsung delays Bioepis Nasdaq float to H2
Samsung Bioepis, the pharmaceutical arm of the South Korean conglomerate, has decided to postpone its Nasdaq IPO due to valuation issues and to make way for the listing of Samsung BioLogics.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts